Mega Lifesciences PCL (BKK:MEGA)
Thailand
· Delayed Price · Currency is THB 35.75
+0.75 (2.14%)
At close: Mar 6, 2026
Mega Lifesciences PCL Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 14,147 | 15,344 | 15,681 | 15,686 | 14,136 | Upgrade
|
| Other Revenue | 47.34 | 41.09 | 34.41 | 40.64 | 36.67 | Upgrade
|
| Revenue | 14,195 | 15,385 | 15,716 | 15,727 | 14,172 | Upgrade
|
| Revenue Growth (YoY) | -7.74% | -2.10% | -0.07% | 10.97% | 12.36% | Upgrade
|
| Cost of Revenue | 6,764 | 7,590 | 8,586 | 8,647 | 8,225 | Upgrade
|
| Gross Profit | 7,431 | 7,796 | 7,130 | 7,080 | 5,947 | Upgrade
|
| Selling, General & Admin | 4,481 | 4,385 | 4,191 | 4,359 | 3,769 | Upgrade
|
| Operating Expenses | 4,481 | 4,385 | 4,191 | 4,359 | 3,769 | Upgrade
|
| Operating Income | 2,950 | 3,411 | 2,939 | 2,722 | 2,178 | Upgrade
|
| Interest Expense | -55.08 | -38.49 | -31.25 | -28.73 | -28.28 | Upgrade
|
| Interest & Investment Income | 83.52 | 61.74 | 60.69 | 39.82 | 10.03 | Upgrade
|
| Earnings From Equity Investments | -0.33 | 0.15 | 0.07 | 0.18 | -1.51 | Upgrade
|
| Currency Exchange Gain (Loss) | -573.9 | -1,082 | -706.57 | -138.16 | 118.52 | Upgrade
|
| EBT Excluding Unusual Items | 2,404 | 2,352 | 2,262 | 2,595 | 2,277 | Upgrade
|
| Pretax Income | 2,404 | 2,352 | 2,262 | 2,595 | 2,277 | Upgrade
|
| Income Tax Expense | 492.21 | 339.63 | 269.06 | 354.63 | 336.02 | Upgrade
|
| Earnings From Continuing Operations | 1,912 | 2,013 | 1,993 | 2,240 | 1,941 | Upgrade
|
| Minority Interest in Earnings | 0.02 | -0.07 | 0.05 | 1.49 | 5.97 | Upgrade
|
| Net Income | 1,912 | 2,012 | 1,993 | 2,242 | 1,947 | Upgrade
|
| Net Income to Common | 1,912 | 2,012 | 1,993 | 2,242 | 1,947 | Upgrade
|
| Net Income Growth | -4.99% | 0.99% | -11.10% | 15.14% | 39.79% | Upgrade
|
| Shares Outstanding (Basic) | 872 | 872 | 872 | 872 | 872 | Upgrade
|
| Shares Outstanding (Diluted) | 872 | 872 | 872 | 872 | 872 | Upgrade
|
| EPS (Basic) | 2.19 | 2.31 | 2.29 | 2.57 | 2.23 | Upgrade
|
| EPS (Diluted) | 2.19 | 2.31 | 2.29 | 2.57 | 2.23 | Upgrade
|
| EPS Growth | -4.99% | 0.99% | -11.10% | 15.14% | 39.79% | Upgrade
|
| Free Cash Flow | 2,107 | 2,154 | 1,652 | 1,692 | 2,575 | Upgrade
|
| Free Cash Flow Per Share | 2.42 | 2.47 | 1.90 | 1.94 | 2.95 | Upgrade
|
| Dividend Per Share | 1.600 | 1.600 | 1.600 | 1.600 | 1.380 | Upgrade
|
| Dividend Growth | - | - | - | 15.94% | 53.33% | Upgrade
|
| Gross Margin | 52.35% | 50.67% | 45.37% | 45.02% | 41.97% | Upgrade
|
| Operating Margin | 20.78% | 22.17% | 18.70% | 17.30% | 15.37% | Upgrade
|
| Profit Margin | 13.47% | 13.08% | 12.68% | 14.25% | 13.74% | Upgrade
|
| Free Cash Flow Margin | 14.84% | 14.00% | 10.51% | 10.76% | 18.17% | Upgrade
|
| EBITDA | 3,154 | 3,614 | 3,146 | 2,917 | 2,378 | Upgrade
|
| EBITDA Margin | 22.22% | 23.49% | 20.02% | 18.55% | 16.78% | Upgrade
|
| D&A For EBITDA | 203.96 | 202.84 | 207.49 | 195.24 | 200.2 | Upgrade
|
| EBIT | 2,950 | 3,411 | 2,939 | 2,722 | 2,178 | Upgrade
|
| EBIT Margin | 20.78% | 22.17% | 18.70% | 17.30% | 15.37% | Upgrade
|
| Effective Tax Rate | 20.47% | 14.44% | 11.90% | 13.67% | 14.76% | Upgrade
|
| Revenue as Reported | 14,278 | 15,447 | 15,776 | 15,767 | 14,301 | Upgrade
|
| Advertising Expenses | 1,255 | 1,232 | 1,323 | 1,266 | 1,052 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.